Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 6/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502330 | 0.92 | JAK2 (0.49) | JAK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2877235 | 0.86 | JAK2 (0.48) | JAK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL3502677 | 0.86 | JAK2 (0.43) | JAK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL3502680 | 0.86 | JAK2 (0.43) | JAK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2875582 | 0.83 | JAK2 (0.46) | JAK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2878390 | 0.83 | JAK2 (0.40) | JAK2CSNK2A1CSNK2A2CSNK2BCLK2 | |
| SCHEMBL2876749 | 0.82 | JAK2 (0.60) | JAK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL3499509 | 0.81 | JAK2 (0.47) | JAK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2878274 | 0.80 | JAK2 (0.42) | JAK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2879736 | 0.80 | JAK2 (0.74) | JAK2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| EP-2200612-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009035575-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | JAK2 1/4885CSNK2A1 278/4885CSNK2A2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.